Focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Employees: 501-1000
Total raised: $160M
Founded date: 1994
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.08.2012 | Series C | $80M | - |
| 13.09.2010 | Series B | $70M | - |
| 11.03.2009 | - | $10M | - |
Mentions in press and media 11
| Date | Title | Description |
| 15.08.2012 | RELYPSA ANNOUNCES $80 MILLION PRIVATE FINANCING TRANSACTION | - |
| 15.08.2012 | Relypsa Announces $80M Series C Round | SANTA CLARA, CA, Relypsa, Inc. today announced an $80 million Series C preferred stock financing, including participation from both new and existing investors. >> Click here for more funding data on Relypsa >> To export Rely... |
| 15.08.2012 | Relypsa completes $80M round as it preps pivotal heart study | Relypsa has put the finishing touches on its whopping $80 million C round from some high-profile biotech investors as it sets the stage for a pivotal trial of its lead drug. The money--which follows a $70 million round two years ago--will b... |
| 13.10.2010 | Healthcare VC deals tick up during the third quarter | Healthcare-related startups in search of cash have more to be happy about these days as venture capital deals jumped 33 percent during the third quarter, compared to the prior quarter, according to a report by New York-based research firm C... |
| 13.10.2010 | Healthcare venture deals jump 33 percent in third quarter | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermin... |
| 13.09.2010 | Relypsa Raises $70M in Series B Financing | Relypsa, Inc., a Santa Clara, CA-based biopharmaceutical company developing non-absorbed polymeric drugs, completed a $70m Series B financing. The round was led by OrbiMed Advisors, LLC, with participation from existing investors New Leaf V... |
| 11.03.2009 | Heart drug co. Relypsa gets $10M more to complete trials | Pharmaceutical company Relypsa announced that its investors extended its first round of funding by $10 million to a total $43 million to help it finish phase-two clinical trials on its lead drug candidate, a treatment that could alleviate s... |
| 29.10.2007 | Relypsa raises $33M for polymer drugs | See our story on this Santa Clara, Calif., biotech at VentureBeat Life Sciences. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transformative technology and transact. O... |
| 29.10.2007 | Amgen, Relypsa and the art of the biotech-spinout-startup-restart | (UPDATED: See below.) A common dilemma in biotech acquisitions is how to keep a startup’s entrepreneurial management happy and productive when they’ve just been assimilated by the Borg. The answer, often enough, is not to bother, and to let... |
| - | Healthcare venture deals jump 33 percent in third quarter | Smile, healthcare entrepreneurs. Health startups in search of cash have more to be happy about because healthcare venture capital deals jumped 33 percent in the third quarter compared to the prior quarter, according to a new report from New... |
Show more